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Abstract
Background: Mendelian models for predicting who may carry an inherited deleterious mutation
of known disease genes based on family history are used in a variety of clinical and research
activities. People presenting for genetic counseling are increasingly reporting risk-reducing medical
interventions in their family histories because, recently, a slew of prophylactic interventions have
become available for certain diseases. For example, oophorectomy reduces risk of breast and
ovarian cancers, and is now increasingly being offered to women with family histories of breast and
ovarian cancer. Mendelian models should account for medical interventions because interventions
modify mutation penetrances and thus affect the carrier probability estimate.
Methods: We extend Mendelian models to account for medical interventions by accounting for
post-intervention disease history through an extra factor that can be estimated from published
studies of the effects of interventions. We apply our methods to incorporate oophorectomy into
the BRCAPRO model, which predicts a woman's risk of carrying mutations in BRCA1 and BRCA2
based on her family history of breast and ovarian cancer. This new BRCAPRO is available for clinical
use.
Results: We show that accounting for interventions undergone by family members can seriously
affect the mutation carrier probability estimate, especially if the family member has lived many years
post-intervention. We show that interventions have more impact on the carrier probability as the
benefits of intervention differ more between carriers and non-carriers.
Conclusion: These findings imply that carrier probability estimates that do not account for
medical interventions may be seriously misleading and could affect a clinician's recommendation
about offering genetic testing. The BayesMendel software, which allows one to implement any
Mendelian carrier probability model, has been extended to allow medical interventions, so future
Mendelian models can easily account for interventions.
Background
People who are concerned that their family has a high
prevalence of disease may seek counseling to assess their
probability of carrying inherited genetic mutations that
cause disease [1]. The carrier probability is a crucial com-
ponent in a person's decision to take a genetic test, to
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undergo frequent disease screening, or to consider pro-
phylactic medical interventions.
To aid such people ("consultands"), genetic counselors
use statistical models that predict whether the consultand
carries deleterious mutations by using the consultand's
reported family history of disease. Mendelian models use
Mendel's laws and Bayes's rule to combine family history
information with each mutation's known prevalence and
penetrance to determine the probability that the con-
sultand is a mutation carrier [2]. For syndromes whose
onset is apparent early in life and where the mutations
have complete penetrance, the carrier probability from a
Mendelian model can be computed from simple mathe-
matical formulae or tables of risks [1]. But for complex
syndromes, the Mendelian model must account for many
more factors, such as age-dependent incomplete pene-
trances, potential censoring of disease whose onset may
not occur over a lifetime, and environmental determi-
nants [3].
For complex syndromes, computing the carrier probabil-
ity from a Mendelian model requires software. The trou-
ble of using software is often worthwhile because simple
risk tables often do not provide as accurate a carrier prob-
ability estimate as computing the carrier probability from
a Mendelian model [4]. The freely-available software
package BayesMendel [5] allows anyone to implement a
Mendelian model and is the computational engine
behind BRCAPRO [6,7] and MMRPRO [8]. BRCAPRO
estimates the probability that a consultand carries a dele-
terious mutation in the BRCA1 [MIM 113705] and BRCA2
[MIM 600185] genes, based on family history of breast
and ovarian cancer, while MMRPRO computes the proba-
bility of carrying a mutation in the DNA mismatch repair
genes MLH1 [MIM 120436], MSH2 [MIM 609309], and
MSH6 [MIM 600678] given family history of colorectal
and endometrial cancer. Genetic counselors use BRC-
APRO and MMRPRO via CancerGene [9], which provides
a user-friendly graphical interface. BRCAPRO has a proven
clinical track-record [4] and will be the example Mende-
lian model in this paper. We have incorporated the exten-
sions we describe in this paper into BayesMendel and
BRCAPRO, and these are available for use by genetic
counselors.
Mendelian models can be extended as knowledge accrues
about complex disease genetics, translating cutting-edge
genetic research into use for genetic counselors [3]. In this
paper, we extend Mendelian models to account for medi-
cal interventions undergone by family members. For
example, a woman at high risk of breast or ovarian cancer
may undergo bilateral salpingo-oophorectomy
("oophorectomy"), the removal of the ovaries and fallo-
pian tubes. Although oophorectomy has adverse conse-
quences for other diseases and for quality of life,
oophorectomy halves risk of breast cancer and eliminates
risk of ovarian cancer [10]. However, peritoneal cancer
near the gynecologic tract (which is often indistinguisha-
ble from ovarian cancer) can still occur [11].
Furthermore, a panoply of prophylactic interventions are
now available for familial cancer syndromes, and con-
sultands are increasingly reporting family members who
have undergone interventions. For example, oophorec-
tomy is increasingly exercised by women at high risk of
breast and ovarian cancers, especially BRCA mutation car-
riers. Most studies show that about 50% of BRCA carriers
undergo oophorectomy [12]. Oophorectomy is so com-
monly chosen because it can prevent both breast and
ovarian cancer. Women concerned only about breast can-
cer risk may undergo prophylactic tamoxifen or bilateral
mastectomy; women have attempted to reduce their ovar-
ian cancer mortality with frequent CA-125 tests or trans-
vaginal ultrasounds [12]. Prophylactic interventions are
also available for people at high risk of familial colon and
endometrial cancer, especially those with mutations in
DNA mismatch repair genes. Such individuals may
undergo colectomy [13] or hysterectomy with oophorec-
tomy [14], and these interventions have implications for
MMRPRO.
Medical interventions must be accounted for by Mende-
lian models for two reasons. First, the act of a relative
choosing to undergo intervention may imply that that rel-
ative knows that she is at high risk and could be a carrier,
unbeknownst to the consultand. Second, interventions
alter mutation penetrances. Oophorectomy reduces risk,
in carriers, of breast cancer by 54% [15] and of ovarian or
peritoneal cancer from 80% [11] to 96% [16]. Ignoring
interventions means that the model untenably assumes
that family members who have undergone intervention
have the same penetrances as those who have not.
Currently, except for BRCAPRO, other mutation predic-
tion models ignore the effects of medical interventions
taken by family members. Ignoring oophorectomy can
seriously affect the BRCA carrier probability estimate, as
for the family in figure 1. In this family, a sister has never
developed cancer, but she underwent oophorectomy at a
young age. Also, the mother's peritoneal cancer after
oophorectomy is at a very old age, as is the aunt's cancer.
Cancer at old ages is usually weak evidence of a BRCA
mutation, and ignoring the oophorectomies, the con-
sultand's BRCAPRO carrier probability estimate is only
3%. However, the mother lived more of her life without
ovaries, so accounting for her oophorectomy is important.
Getting cancer after oophorectomy is more evidence for a
mutation and when BRCAPRO accounts for oophorec-
tomy (as detailed in the Methods), the carrier probabilityBMC Medical Genetics 2007, 8:13 http://www.biomedcentral.com/1471-2350/8/13
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jumps to 13%. This difference is especially critical because
many counselors offer genetic testing to the consultand
once the probability hits 10% [17] and health insurers
may not pay for the test unless the probability is high
enough [18].
Table 1 shows how the BRCAPRO carrier probability
changes when accounting for oophorectomy for different
family histories based on figure 1. Table 1 shows that
accounting for the sister's oophorectomy is not as impor-
tant as the mother's oophorectomy. This is because the
mother developed cancer after oophorectomy. In particu-
lar, we estimate that while carriers have a reduction of
88% in the risk of ovarian or peritoneal cancer after
oophorectomy (see Methods), non-carriers enjoy a 95%
risk reduction [19]. Thus getting peritoneal cancer after
oophorectomy is additional evidence for being a carrier.
Also in table 1, if the sister develops breast cancer at 56,
accounting for oophorectomies changes the carrier prob-
abilities from 11% to 29%, which might affect the deci-
sion to offer testing since 11% is close to the 10%
guideline. If the sister develops peritoneal cancer, the
probability changes from 25% to 44%, a big change, but
genetic testing would probably be offered in either case. If
the mother instead had breast cancer at 80, the carrier
probability only goes from 1% to 1.4%, but is an increase
of 40%. Since interventions multiplicatively affect the car-
rier probability (detailed in Methods), percent change is a
noteworthy metric.
In this paper, we show how to incorporate medical inter-
ventions into Mendelian models. The only extra quantity
needed is a post-intervention factor for those who chose
intervention. This post-intervention factor can be esti-
mated using the reduction in disease hazard caused by the
intervention, which is commonly estimated in studies of
the effects of interventions. We show that, as long as the
consultand accurately reports family history and is aware
of the genetic test results on any relatives, then we do not
need to model the effect of family history and carrier sta-
tus on choosing to (or not to) undergo oophorectomy.
We detail how we chose to incorporate oophorectomy
into BRCAPRO. Given current uncertainties about the
effects of oophorectomy, we show the impact of
oophorectomy for different instructive scenarios. These
scenarios show that the importance of accounting for
interventions increases as the benefits of intervention dif-
fer more between carriers and non-carriers. We have incor-
porated interventions into BayesMendel, allowing anyone
to incorporate any intervention into any Mendelian
model. In particular, oophorectomy has been incorpo-
rated into BRCAPRO and this new BRCAPRO has been
released to counselors for clinical use.
Methods
Computing the Carrier Probability
Mendelian models require knowledge of which disease
each relative developed and the age when it was diag-
nosed. For example, for BRCAPRO, the diseases are age at
ovarian cancer or breast cancer onset. Although there can
be many causes of censoring [20], we restrict to a single
independent non-informative censoring being the mini-
mum of the age alive after which no information is known
or the age of death. In this framework, everyone is eventu-
ally censored but disease history up to that age of censor-
ing is observed. Denote the age at which censoring occurs
for each family member i (i = 0 is the consultand) as Ui.
A Mendelian model considers D  types of diseases that
could occur. Each person has a binary vector indicating
disease history ci = (ci,1, ..., ci,D) where ci,k = 1 indicates that
disease k occurred at age yi,k and let yi = (yi,1, ..., yi,D) be the
vector of all ages of disease occurrence. In yi, the age for
any disease that did not occur is irrelevant, and so can be
set to 0. Denoting disease information as Ti = {yi, ci}, each
person's history is the information Hi = {Ui, Ti} and the
full family history is the collection H = {H0, H1, ...}.
Additionally, each person can have auxiliary variables xi
and let x = {x0, x1, ...}. Auxiliaries can be any extra infor-
mation known by the consultand, for example, environ-
mental factors, genetic test results, or ethnicity. For
example, in BRCAPRO, x0 indicates if the consultand is of
Ashkenazi Jewish ancestry, an ethnic group with increased
prevalence of BRCA mutations. Implicitly, all probabili-
ties in this paper will condition on x, so for simplicity we
only explicitly show x in the conditioning when useful.
Mendelian models assume that individuals independ-
ently inherit one allele from each parent at each auto-
somal locus and that the alleles are either normal or
mutated. Let γi = 0,1 indicate carrying the genotype(s) that
confer(s) disease risk: for example, γi = 1 for a dominant
trait when the member carries at least 1 mutant allele, but
for a recessive trait γi = 1 implies that the relative carries
two mutant alleles. We call γi the carrier status. The preva-
lence of γi = 1 amongst people with consultand-specific
auxiliaries x0 is πx.
The aim of a Mendelian model is to compute the con-
sultand's carrier probability P(γ0 = 1|H, x). By Bayes rule,
the odds of the consultand being a carrier is a product of
the carrier odds in the population and the Bayes Factor
(BF):
The BF is a ratio of likelihoods. We compute the likeli-
hood, assuming that each member's phenotype Hi is inde-
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Example Family Tree Figure 1
Example Family Tree. Family tree with breast (Br) and peritoneal (Pe) cancer history, and oophorectomy (Oo). The arrow 
points to the consultand. Circles are females, squares are males. Slash means the relative died, dark shape means the relative 
developed cancer, light shape and no slash means the relative is alive with no cancer, and the age of those outcomes is below 
each member.
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Table 1: Effect on BRCAPRO Carrier Probability of Ignoring vs. Including Oophorectomy for Families Based on Figure 1.
Family Ignoring all Oophorectomies Including all Oophorectomies
As in Figure 1 3% 13%
No oophorectomy for sister 3% 12%
No oophorectomy for mother 3% 4%
Sister has breast cancer at 56 11% 29%
Sister has peritoneal cancer at 56 25% 44%
Mother has only breast cancer at 80 1% 1.4%BMC Medical Genetics 2007, 8:13 http://www.biomedcentral.com/1471-2350/8/13
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pendent of all other members' phenotypes H-i  and
auxiliaries x-i given that member's carrier status γi and aux-
iliary variables xi [21]:
P(Hi|γi, x, H-i) = P(Hi|γi, xi).   (2)
The likelihood is
This depends on family history only through the contribu-
tions P(Hi|γi, xi), so we focus on computing these. To ease
notation, auxiliaries xi are always implicitly conditioned
on, and will be made explicit only when useful. For more
details, a discussion of underlying assumptions, and an
explicit derivation of the Bayes Factor [5,21].
Each person's likelihood contribution P(Hi|γi, xi) will be
computed assuming that competing risks are independent
given carrier status and auxiliaries [20]. This is plausible
for BRCAPRO because time to ovarian cancer and ipsi/
contra-lateral breast cancers appear to be mutually inde-
pendent in BRCA mutation carriers, except for depend-
ence caused by medical interventions like oophorectomy
[22,23] and interventions are explicitly handled in this
paper. Auxiliaries xi can include all information necessary
to make the assumption more plausible [20]. Thus for
simplicity and relevance to BRCAPRO, we restrict to inde-
pendent competing risks.
Under independent competing risks, define the hazard for
each disease k > 0 at age T given carrier status as λk(y|γ).
The disease-specific survival, the probability of surviving
disease k to age y, is
The disease-specific density, the probability of getting dis-
ease k at age y, is
fk(y|γ) = λk(y|γ) × Sk(y|γ).   (5)
Each likelihood contribution P(Hi|γi) is an ignorably
right-censored survival likelihood contribution, which is
the product of disease-specific densities for diseases that
occurred and the disease-specific survivals for diseases
that did not occur [20]:
Incorporating Medical Interventions
Medical interventions censor the natural time to disease,
leaving only the time to disease after intervention. Along
with pre-intervention quantities Yi, Ci, Ui, there is the age
of intervention Ii and post-intervention quantities: post-
intervention disease types  , ages of disease  , and cen-
soring age  . Let   = { ,  } and the post-interven-
tion history be   = { ,  }. If intervention occurs,
then set Ui  =  Ii. Furthermore, any genetic test results
known on relatives can be included as an auxiliary xtest.
Genetic test results provide important information, and
Mendelian models can account for imperfect test sensitiv-
ity and specificity [5,24].
To compute each family member's likelihood contribu-
tion including potential interventions, figure 2 shows the
conditional dependencies between all pre/post-interven-
tion quantities [25]. This graph shows the flow of infor-
mation from carrier status to pre-intervention disease to
intervention to post-intervention disease and will deter-
mine which quantities that the contribution requires or
can ignore. The graph does not show any quantities in the
intervention decision that are obviously unrelated to car-
rier status, like desire for children. Such quantities can be
ignored because they provide no information about car-
rier status. In the graph, Ti, xtest, Ui, H-i are the four factors
that point to choosing intervention Ii. But since Ui does
not connect back to γi, it provides no information on car-
rier status. Thus only Ti, xtest, and H-i affect a person's deci-
sion to have an intervention and could yield information
about carrier status. The likelihood contributions in equa-
tion (6) clearly depend on Ti and xtest. In addition, the con-
tributions also condition on H-i: H-i only disappears from
(6) because of assumption (2). The expressions below will
explicitly show the conditioning on H-i to clarify that H-i is
accounted for by the likelihood contributions. Thus the
likelihood contributions contain all quantities related to
both carrier status and intervention.
Each person's likelihood contribution depends on
whether intervention was chosen. First consider the con-
tribution from a person who did not choose intervention:
P(Ii > ui, Hi|γi, xi, H-i) = P(Ii > ui|Hi, γi, xi, H-i) × P(Hi|γi, xi).   (7)
Note that the second factor is the usual contribution from
equation (6) that does not handle interventions. The first
factor tries to extract information about carrier status from
choosing not to undergo intervention. But by figure 2, as
long as the full family history and any genetic test results
are known, all three paths back to γi are blocked. Thus
there is no information about carrier status by choice of
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intervention once the full family history and genetic test
results are known. Thus the first factor is independent of
γi and drops out of the likelihood. So the contribution if
intervention was not chosen (7) is the same as of equation
(6) that does not consider interventions:
P(Ii > ui, Hi|γi, xi, H-i) ∝ P(Hi|γi, xi).
Next, the contribution from a person choosing interven-
tion at age I is
P(Ii = I, Hi, |γi, xi, H-i) = P(| Ii = I, Hi, γi, xi) × P(Ii =
I|Hi, γi, xi, H-i) × P(Hi|γi, xi).
The last two factors can be treated the same as in equation
(7), so the contribution is
∝ P(| Ii = I, Hi, γi, xi)P(Hi|γi, xi).   (8)
The second factor is the pre-intervention contribution,
and the first factor is an analogous post-intervention fac-
tor.
The post-intervention factor in (8) can be estimated from
survival data. By figure 2, conditioning on Ii (as the post-
intervention factor does) breaks all links from   to both
 and γi. Thus   is independent non-informative cen-
soring given Ii, so standard survival analysis can estimate
the post-intervention disease hazards  (y|Ii, Hi, γi). A
simple way to do this is to fit a Cox model for time to dis-
ease with auxiliaries, pre-intervention disease history, and
intervention age as time-dependent covariates [26]. The
hazard ratios from this Cox model are multiplied with a
pre-intervention hazard estimate (perhaps from the same
dataset, or taken from other penetrance studies) to yield
the post-intervention hazard. Then the post-intervention
disease-specific survival is
Note that the hazards are cumulated starting from inter-
vention age I. The post-intervention disease-specific den-
sity is  . The likelihood contribution for a person
who chose intervention is
The contributions to the Bayes Factor in equation (1) are
the ratio of likelihood contributions (10) for γi = 1 to γi =
0. [20] The post-intervention part of this ratio is
Note that if the hazard ratios between carriers and non-
carriers are equal, then at the age of oophorectomy itself,
the densities for carriers and non-carriers are equal to each
other (and same for the survivals), and thus (11) is one.
At ages beyond the age of oophorectomy, the hazards start
cumulating as in equation (9), and the densities and sur-
vivals will begin to differ and (11) will differ from one.
The amount of information in oophorectomy can be
measured by the ratio of hazard ratios of carriers to non-
carriers; the further this ratio is from one, the further (11)
is one will be from one, and thus the more important it is
to account for oophorectomy. However, a hazard ratio of
one still has implications for all post-oophorectomy ages,
so we stress that ratio of one still must be accounted for.
Incorporate Oophorectomy into BRCAPRO
Including an intervention requires estimating post-inter-
vention disease-specific hazards, the simplest way being
multiplying each pre-intervention hazard by a hazard
ratio to get post-intervention hazards. BRCAPRO uses pre-
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Relationships amongst pre/post-intervention quantities Figure 2
Relationships amongst pre/post-intervention quanti-
ties. Graph showing conditional dependencies of pre/post-
intervention quantities. Γ contains the carrier status of each 
family member γi. The factors affecting each member's choice 
of age of intervention Ii are pre-intervention disease history 
Yi, Ci, genetic test results xtest, pre-intervention censoring age 
Ui, and everyone else's family history H-i. Post-intervention 
disease history is  ,   and age last known alive  . For 
simplicity, auxiliaries xi are not shown.
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oophorectomy hazards estimated by [27]. We use the
most recently estimated hazard ratios for obtaining post-
oophorectomy breast cancer hazards for mutation carriers
[15]. It is critical to consider all factors that could modify
the appropriate hazard ratio to use. For example, [15] esti-
mates hazard ratios for breast cancer within groups
defined by pre-oophorectomy disease history, age at
oophorectomy, time since oophorectomy, and by BRCA1
vs. BRCA2. Although [15] does not formally test if the
hazard ratios differ within each group, we must infor-
mally assess whether the differences they found are
strongly statistically significant. For example, [15] finds
that those with BRCA1 mutations have a hazard ratio of
0.43 (0.29, 0.65) and those with BRCA2 mutations a haz-
ard ratio of 0.57 (0.28, 1.15). Since these two estimates
must be nearly independent, we can calculate a p-value of
0.50 for the difference in hazard ratios between the two
loci; thus we are justified in using the same hazard ratio
for both loci. For age at oophorectomy, we cannot calcu-
late a p-value, but the degree of overlap of the confidence
intervals between age ranges in [15] suggests that the dif-
ferences in the hazard ratio are probably statistically insig-
nificant, and thus justifies the use of a common hazard
ratio over all ages. The overall hazard ratio found by [15]
was 0.46 (0.32, 0.65), but for 15 years after oophorec-
tomy, they find a hazard ratio of 1.30 (0.51, 3.30). The
two intervals overlap, but it's possible that the two are sig-
nificantly different. However, neither [16] nor [28]
noticed this in their data, and the 1.30 hazard ratio is esti-
mated quite imprecisely, making us hesitant to use this in
a model for clinical decision-making. Also, if only a few
modifying factors exist, using a single hazard ratio for eve-
ryone is advantageous because this overall hazard ratio
would be most precisely estimated and is relevant for
most consultands. Thus we use the overall hazard ratio of
0.46.
For oophorectomy and ovarian/peritoneal cancers among
mutation carriers, we combined three papers: one retro-
spective study reports an overall hazard ratio of 0.04 with
CI (0.01,0.16) [16] and two prospective studies report
0.15 with CI (0.02,1.31) [28] and 0.20 with CI
(0.07,0.58) [11]. Since all references combine ovarian
cancer and primary peritoneal carcinoma into a single
endpoint, separate effects of oophorectomy on each can-
cer cannot be estimated, so we combine them into a single
endpoint. All papers report that these hazard ratios do not
depend on pre-oophorectomy disease history, age at
oophorectomy, time since oophorectomy, or by BRCA1
vs. BRCA2. We combine these three results with a fixed-
effect meta-analysis [29] to average the hazard ratios
weighted by their inverse variances, yielding an estimate
of 0.12 with CI (0.05,0.25).
Unfortunately, there are no comparable studies of
oophorectomy in BRCA  non-carriers, only studies that
mix carriers with non-carriers. A population-based study
found a hazard ratio of 0.50 [30] and another study
among women with family history of breast cancer
reported a hazard ratio of 0.41 [31]. Since these ratios are
close to the carrier ratio, we set non-carriers to have the
same hazard ratio of 0.46 as the carriers. For ovarian/peri-
toneal cancer, the only comparable study among non-car-
riers reports a hazard ratio of 0.05 with CI (0.01,0.22)
[19]. Although [19] doesn't report a p-value testing for dif-
ferent effects of oophorectomy in carriers vs. non-carriers,
since their two estimates should be nearly independent,
we calculate a p = 0.048 that the two effects are different.
Thus we set the non-carrier hazard ratio for oophorec-
tomy to 0.05.
Results
Including Oophorectomy into BRCAPRO
This section computes the post-intervention contribu-
tions to the BRCAPRO Bayes Factor (as in equation (11))
from a woman who underwent oophorectomy at age 35,
for all three possibilities of developing breast or perito-
neal cancer, or current age without either cancer (remem-
ber that ovarian cancer is eliminated by oophorectomy,
but the closely-related peritoneal cancer can still occur).
Figure 3 plots a woman's post-oophorectomy contribu-
tion to the BRCA1 Bayes Factor, by accounting for her
oophorectomy at age 35 (solid lines), ignoring her
oophorectomy (dashed lines), or censoring her at the age
of oophorectomy (dotted lines). A woman can get breast
or peritoneal cancer, or no cancer, at the age indicated on
the x-axis. Since the effect of oophorectomy in non-carri-
ers has not been well-studied, each panel of figure 3 con-
siders four different possible effects of oophorectomy in
non-carriers: the top left has the equal hazard reductions
in carriers and non-carriers, the top right has more hazard
reduction in non-carriers, the bottom left has more hazard
reduction in carriers, and bottom right has extreme (but
reasonable) difference in hazard reduction between carri-
ers and non-carriers. The dashed and dotted lines are the
same in all figures since they never account for the effect
of oophorectomy.
The top left panel of figure 3 uses the equal hazard ratios
(see Methods) of 0.46 for breast cancer and 0.12 for peri-
toneal cancer for carrier and non-carriers. Equal hazard
ratios means that carriers and non-carriers benefit the
same from oophorectomy. Ignoring oophorectomy leads
to underestimated contributions in all cases, and thus the
carrier probability will be underestimated, as for the fam-
ily in figure 1. At at age 35, the solid and dashed lines are
the same because the hazard ratios in carriers and non-car-
riers are the same. The solid and dashed lines diverge atBMC Medical Genetics 2007, 8:13 http://www.biomedcentral.com/1471-2350/8/13
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older ages, as the woman lives more of her life without
ovaries, and by age 90 there is roughly a factor of five
change in the contribution. For a woman who did not get
cancer, in this scenario, it is better to censor her at her age
of oophorectomy than at the latest age known without
cancer.
In the top right panel of figure 3, the non-carrier hazard
ratios decrease to 0.32 and 0.05 (the lower end of the CIs
from Methods) for breast and peritoneal cancer respec-
tively. In this scenario, oophorectomy benefits non-carri-
ers more than carriers and thus developing cancer after
oophorectomy is additional evidence for being a carrier.
Indeed, in this panel, there is more difference between the
solid and dashed lines than in the top left panel. Further-
more, not developing cancer after oophorectomy is usu-
ally less evidence for being a non-carrier since
oophorectomy naturally lowers cancer risk for everyone.
Effect of ignoring and accounting for oophorectomy on BRCAPRO Figure 3
Effect of ignoring and accounting for oophorectomy on BRCAPRO. Effect of ignoring and accounting for an 
oophorectomy at age 35 on a relative's post-oophorectomy contribution to the BRCAPRO Bayes Factor for BRCA1. Solid lines 
account for the oophorectomy, but dashed lines ignore the oophorectomy, and the dotted line censors the relative at their age 
of oophorectomy. The person got peritoneal cancer, breast cancer, or no cancer at the age indicated on the x-axis. The four 
panels vary the hazard reduction due to oophorectomy. In the top left, the hazard reduction due to oophorectomy is the same 
for BRCA1 carriers and non-carriers: 0.46 and 0.12, on time to subsequent breast and peritoneal cancer respectively. In the top 
right, the hazard reduction for oophorectomy in BRCA1 non-carriers increases to 0.32 and 0.05 for breast and peritoneal can-
cer respectively. In the bottom left, the hazard reduction for oophorectomy in BRCA1 carriers decreases to 0.65 and 0.25 for 
breast and peritoneal cancer respectively. The bottom right has hazard reductions for breast cancer of 0.65 and 0.32 in carriers 
and non-carriers respectively and hazard reductions for peritoneal cancer of 0.25 and 0.05 in carriers and non-carriers respec-
tively.
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The bottom left panel of figure 3 increases the non-carrier
hazard ratios to 0.65 and 0.25 (the upper end of the CIs
from Methods) for breast and peritoneal cancer respec-
tively. In this scenario, carriers benefit more from
oophorectomy. Now cancer after oophorectomy is less
evidence of being a carrier, so the solid lines accounting
for oophorectomy decrease and cross over the dashed
lines ignoring oophorectomy. In this case, ignoring
oophorectomy could lead to either under- or over-estima-
tion of the BF contributions and carrier probability,
depending on the ages of the cancers after oophorectomy.
The bottom right panel of figure 3 shows an extreme, but
reasonable, case where oophorectomy is most informa-
tive about carrier status. The benefit to non-carriers is set
to 0.32 and 0.05 (the lower end of the CIs from Methods)
and for carriers is set to 0.65 and 0.25 (the upper end of
the CIs from Methods) for breast and peritoneal cancer
respectively. These non-carrier benefits are as different as
possible from the carrier benefits, but plausible since they
are within the CIs. Using these benefits, for breast cancer
by age 90, there is a factor of 8 underestimation of the
contributions if oophorectomy is ignored from someone
with breast cancer, and 15 if peritoneal cancer. Although
the difference between hazard ratios of 0.25 versus 0.05
seems small, their ratio is large, and it is the ratio that mat-
ters. If we used the hazard ratios in the top right panel to
estimate the carrier probability for the family in figure 1,
the carrier probability increases to 12%. Furthermore, if
the mother in figure 1 got peritoneal cancer at age 80
instead of breast cancer, the carrier probability ignoring
her oophorectomy is 25%, the probability goes to 31%
under equal hazard ratios of 0.12, the probability goes to
39% assuming hazard ratios of 0.12 and 0.05 for carriers
and non-carriers (as in the top left panel and as set in BRC-
APRO), and the probability goes to 43% for the hazard
ratios in the bottom right panel.
Discussion
People with a family history of disease may undergo pro-
phylactic interventions to prevent future disease. Interven-
tions are informative about the carrier probability not
only because interventions reduce the penetrance of
mutations, but also because only those with high disease
risk (and thus potential mutation carriers) will opt for it.
Furthermore, as interventions become more commonly
undergone (most studies show that about 50% of BRCA
carriers undergo oophorectomy [12]) and consultands
report more family members as having undergone inter-
vention, it is increasingly important that mutation predic-
tion models account for interventions. Extending
Mendelian models to reflect the latest research findings
helps answer the call to translate genetic research for use
by genetic counselors [3].
Incorporating interventions into Mendelian mutation
prediction models requires only a post-intervention factor
multiplying the likelihood contribution from family
members with the intervention. The only new quantities
required are the post-intervention disease hazards which
can be estimated by multiplying the pre-intervention haz-
ards by hazard ratios for the effect of intervention that can
be found in published studies of intervention effects. We
extended the BayesMendel software to handle interven-
tions, and the new BRCAPRO that accounts for oophorec-
tomy is available for clinical use. Other interventions that
BayesMendel could incorporate are prophylactic
tamoxifen therapy into BRCAPRO, and colectomy and
hysterectomy with oophorectomy into MMRPRO.
To incorporate oophorectomy into BRCAPRO, we relied
on hazard ratios for the effect of oophorectomy in BRCA
mutation carriers found in previous studies [11,16,28],
and for non-carriers and peritoneal cancer [19]. Although
no comparable studies exist for breast cancer hazard ratios
in non-carriers, existing studies that likely involve pre-
dominantly non-carrier subjects [30,31] show hazard
ratios similar to those in carriers, so we set hazard ratios in
non-carriers equal to that of carriers. However, it is more
likely that BRCA  mutation carriers benefit less from
oophorectomy because they have earlier age of onset of
breast cancer. Since our incorporation sets equal benefits
to prevent breast cancer, this may underestimate the
impact of oophorectomy, but further studies of oophorec-
tomy in non-carriers are needed to clarify this situation.
Fortunately, forthcoming prospective studies of the bene-
fit of oophorectomy in women at high risk of ovarian can-
cer, such as GOG-0199 [32], could provide the data
required to refine the incorporation of oophorectomy
into BRCAPRO. Such studies will include BRCA mutation
non-carriers, allowing estimation of the intervention haz-
ard ratio in non-carriers.
Figure 3 shows the effect of incorporating oophorectomy
for different possible hazard ratios. All four panels of fig-
ure 3 show that accounting for oophorectomy is most
important for older family members with oophorectomy.
Ignoring oophorectomy leads to underestimated carrier
probabilities, unless carriers benefit more from oophorec-
tomy, as in the lower left panel of figure 3. The amount of
underestimation depends on how informative post-
oophorectomy diseases are for carrier status. The top left
panel of figure 3 is for equal carrier and non-carrier hazard
ratios, and the effect of incorporating oophorectomy here
is not as great as in the two right panels, where carriers
benefit less from oophorectomy. Interventions are most
informative about carrier status when carriers benefit less
than non-carriers, as measured by the ratio of the hazard
ratios in carriers to non-carriers.BMC Medical Genetics 2007, 8:13 http://www.biomedcentral.com/1471-2350/8/13
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Our incorporation of interventions shows that there is no
information about carrier status in whether a relative
chooses intervention or not, as long as the full family his-
tory and genetic test results are known. This is reflected in
the fact that the first factor of equation (7) is ignorable.
This factor will not be ignorable if the relative based her
intervention decision on factors predictive of carrier status
that are not available to the consultand. For example, if a
consultand is unaware of genetic test results on a relative
who opted for or against intervention based on those test
results, then the first factor is not ignorable. However, the
first factor can be estimated from a survival analysis of age
at intervention given pre-intervention disease history and
carrier status. Prospective studies such as GOG-0199
could provide the required data.
Although this paper has emphasized using Mendelian
models in genetic counseling, other applications exist.
Mendelian models can help gene characterization
research by helping to select high-risk individuals for
studies (such as in GOG-0199) and also to help build sta-
tistical models that estimate individualized disease risks
[7]. Both applications benefit from the incorporation of
interventions into Mendelian models.
Conclusion
These results show that not accounting for medical inter-
ventions can lead to seriously misleading carrier probabil-
ity estimates that could affect a clinician's
recommendation about offering genetic testing. This is
especially true if an intervention was undergone long ago
by a family member or if the intervention has different
effects on carriers versus non-carriers. The new BayesMen-
del software has been extended to allow medical interven-
tions, so any carrier probability model can easily account
for interventions.
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